Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AllerT SC
- Development stage
- Unknown
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
AllerT SC is a subcutaneous immunotherapy product developed for the treatment of moderate to severe allergic rhinitis caused by birch tree pollen. It is administered via subcutaneous injection and is designed to induce immune tolerance to birch pollen allergens, thereby reducing allergic symptoms. The mechanism of action involves modulating the immune response, likely through induction of allergen-specific regulatory T cells and reduction in IgE-mediated hypersensitivity reactions. Clinical trials have evaluated its safety and efficacy compared to placebo in adults with birch pollen allergy[1][2].
- Brand names
- AllerT SC
- Other names
- AllerT SC
02
Targets
Allergen-specific IgE/IgG-recognized allergen epitopes
Beyond the preview
Go deeper on AllerT SC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AllerT SC.